Overcome the Unique Drug Development Hurdles to Deliver Safe, Efficacious and Non-invasive anti-VEGF and non-anti-VEGF Therapeutics to Address the Significant Unmet Medical Need in Retinal Vascular Diseases
Welcome to the Retinal Vascular Disease Drug Development Summit
Novel Disruptive Therapeutic & Delivery Approaches to Treat Wet-AMD, DR & DME
The incidence of wet-AMD and diabetic eye diseases are increasing globally. Current treatment options place a significant treatment burden on patients, but a flourishing pipeline of innovative therapeutic options with high efficacy and lower invasiveness is disrupting the status quo.
The Retinal Vascular Disease Drug Development Summit will unite the industry leaders at the forefront of developing and delivering these innovative treatments, providing you with an unparalleled quality of technical insights specifically enabling you to progress your retinal vascular disease pipeline more quickly and effectively to get these innovative therapeutics to market.
World-Class Speaker Faculty Includes:
Senior Director - Translational, Experimental Medicine & Retina Clinical lead
Janssen Global Services, LLC
Global Development Lead, Ophthalmology
Senior Director - Medical Affairs & Ophthalmology